You are here

anti-TIGIT

Roche records setback in phase III study of two lung cancer drugs

MSN/Reuters

Tue, 11/26/24 - 11:17 am

Merck stops testing combo drug for skin cancer as more patients discontinue

Reuters

Mon, 05/13/24 - 11:14 am

clinical trials

Novartis retreats from TIGIT, handing $300M candidate back to BeiGene

Fierce Biotech

Tue, 07/11/23 - 10:22 am

ASCO: Gilead and Arcus's Cancer Immunotherapy Combo Faces Scrutiny Over Lower Survival Rates

BioSpace

Sun, 06/4/23 - 04:27 pm

Gilead Sciences

Arcus Biosciences

non-small cell lung cancer

Iteos – and GSK – keep the faith

EP Vantage

Tue, 05/9/23 - 10:40 am

iTeos Therapeutics

Three TIGIT players look to surprise in 2023

EP Vantage

Fri, 01/13/23 - 10:06 am

Gilead Sciences

Arcus Biosciences

ESMO: GSK keeps the faith in anti-TIGIT plans; it's 'not always about being first'

Fierce Biotech

Fri, 09/9/22 - 12:08 pm

Strike 2: Roche flunks another phase 3 lung cancer test to leave TIGIT space reeling

Fierce Biotech

Wed, 05/11/22 - 10:38 am

non-small cell lung cancer

clinical trials

Novartis Deepens BeiGene Oncology Pact, Posts Disappointing Results in CSU

BioSpace

Mon, 12/20/21 - 10:49 am

Roche builds case for TIGIT combo in untreated lung cancer

Pharmaforum

Fri, 12/10/21 - 10:50 am

Why Arcus Biosciences Stock Is On Fire Today

Motley Fool

Thu, 11/18/21 - 10:41 am

Arcus Biosciences

Gilead Sciences

Arcus declares cryptic interim win for closely watched anti-TIGIT drug, but you'll have to wait for the data

Endpoints

Wed, 06/23/21 - 10:32 pm

Arcus Biosciences

Arcus nears crunch time for Gilead opt-in

EP Vantage

Thu, 06/10/21 - 10:47 am

Arcus Biosciences

clinical trials

Gilead Sciences

monoclonal antibodies

iTeos busts out early human data for anti-TIGIT antibody. Is it enough to match up with Roche, Merck?

Endpoints

Sun, 04/11/21 - 11:48 pm

iTeos Therapeutics

In early blow to Kenji Yasukawa's R&D revamp, Astellas drops out of the TIGIT race without explanation

Endpoints

Fri, 10/30/20 - 10:17 am